These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 25376291)

  • 1. Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
    Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    Dig Dis; 2014; 32(6):733-9. PubMed ID: 25376291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
    Estfan B; Byrne M; Kim R
    Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Chen L; Su H; Shao H; Xu K; Liang S; Liu J
    Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
    Li J; Wang L; Cong N; Shi C; Bu W; Song J; Chen H
    Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
    Negri FV; Dal Bello B; Porta C; Campanini N; Rossi S; Tinelli C; Poggi G; Missale G; Fanello S; Salvagni S; Ardizzoni A; Maria SE
    Liver Int; 2015 Aug; 35(8):2001-8. PubMed ID: 25559745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
    Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
    Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
    J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
    Zhou L; Li J; Ai DL; Fu JL; Peng XM; Zhang LZ; Wang JY; Zhao Y; Yang B; Yu Q; Liu CZ; Wang HM
    Jpn J Clin Oncol; 2014 Aug; 44(8):711-7. PubMed ID: 24855686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
    Lee FA; Zee BC; Cheung FY; Kwong P; Chiang CL; Leung KC; Siu SW; Lee C; Lai M; Kwok C; Chong M; Jolivet J; Tung S
    Am J Clin Oncol; 2016 Dec; 39(6):609-613. PubMed ID: 24977690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.
    Ogasawara S; Chiba T; Ooka Y; Suzuki E; Inoue M; Wakamatsu T; Tawada A; Yokosuka O
    PLoS One; 2016; 11(8):e0161303. PubMed ID: 27537374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib.
    Tsukui Y; Mochizuki H; Hoshino Y; Kawakami S; Kuno T; Fukasawa Y; Iwamoto F; Hirose S; Yoshida T; Hosoda K; Suzuki Y; Hosoda K; Kojima Y; Hirose Y; Shindou K; Matsuda M; Yagawa S; Tawara A; Kobayashi M; Konishi T; Yamazaki T; Takahashi S; Fuji H; Enomoto N; Omata M
    Hepatogastroenterology; 2012; 59(120):2536-9. PubMed ID: 22497953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
    Shiozawa K; Watanabe M; Ikehara T; Kogame M; Matsui T; Okano N; Kikuchi Y; Nagai H; Ishii K; Makino H; Igarashi Y; Sumino Y
    Hepatogastroenterology; 2014 Jun; 61(132):885-91. PubMed ID: 26158136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.
    Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    Oncology; 2014; 87 Suppl 1():32-6. PubMed ID: 25427731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
    Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
    Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
    Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
    Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
    Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.